The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
Honey, once a simple pantry staple, is now sought after as a natural wellness tool. While it remains a form of sugar, emerging research suggests its unique composition—rich in antioxidants and oligosaccharides—offers distinct benefits over refined sweeteners, potentially aiding in weight control and gut health.
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
The competition between Eli Lilly and Novo Nordisk is reshaping obesity treatment. Learn the clinical differences between Mounjaro and Wegovy, and why international market dynamics matter for patient access.
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
Prescriptions for weight loss drugs have tripled since 2020. Discover the science, social impact, and practical tips for navigating the GLP-1 era safely.
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
